Nov 29, 2022 / 03:55PM GMT
William Olds - Evercore ISI Institutional Equities, Research Division - Research Analyst
Hello. This is Will olds from the Evercore ISI Biotech Equity Research team, and I am delighted to be joined today by Karl Gubitz, the CFO; and Keith Woods, the COO of Argenx to really talk about VYVGART and all the excitement going on there. So I'd love if you guys would just start out with just a snapshot overview of where argenx is this year.
Karl Gubitz - argenx SE - CFO
Thank you, Will. Good morning to everybody. Yes, 2022 has been a really exciting year for us. First, the launch, our global launch. We launched in 3 territories: the U.S. in January, Japan in May and then in Europe, in Germany in September. So a global launch in 3 territories and of course, the launch is going really well. What we've seen is that the MG, we have unmet need is fair. Our strategies are working. Firstly, with physicians that data is resonating, and the first experiences by half is really good. In terms of patients, we've empowered the patients to ask about the disease to -- and for them to
argenx SE at Evercore ISI HealthCONx Conference (Virtual) Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers